# Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

> **NCT03894540** · PHASE1 · TERMINATED · sponsor: **Ipsen** · enrollment: 22 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** IPN60090
- **DRUG:** pembrolizumab
- **DRUG:** paclitaxel
- **DRUG:** IPN60090 single administration

## Key facts

- **NCT ID:** NCT03894540
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-22
- **Primary completion:** 2020-12-21
- **Final completion:** 2020-12-21
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Following an internal portfolio review, Ipsen has made the decision to terminate study D-US-60090-001. Ipsen would like to highlight that early termination was not due to any safety or tolerability issues with IPN60090
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03894540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03894540, "Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03894540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*